News
PFE
27.81
+0.40%
0.11
16 out of 24 health care companies beat topline numbers this week- Earnings scorecard
16 out of 24 health care companies beat topline numbers this week. S&P 500 healthcare index (XLV) traded up 3.01%. The healthcare sector had 24 companies reporting their quarterly earnings this week, with 16 of them beating their numbers. The sector has been in the news with the weight loss saga and marijuana rescheduling.
Seeking Alpha · 6h ago
Pharma R&D productivity seen improving for the first time in years - Deloitte
Healthcare Pharma R&D productivity seen improving for the first time in years - Deloitte. A new report from Deloite says productivity appears to have turned a corner in 2023. The internal rate of return from biopharma companies has been in decline since 2010.
Seeking Alpha · 7h ago
Dividend Champion, Contender, And Challenger Highlights: Week Of May 5
Dividend Champion, Contender, And Challenger Highlights: Week Of May 5. Apple, IBM, and PepsiCo among the companies to increase their dividends in the past week. The Dividend Champions list is a monthly compilation of companies which have consistently increased their annual dividend payouts.
Seeking Alpha · 12h ago
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
Can Pfizer challenge Eli Lilly and Novo Nordisk in the obesity drug market? Pfizer has three experimental obesity drugs in clinical testing. The company has been criticized for failing to advance one of its obesity drugs. Pfizer could acquire another company with a promising obesity drug.
The Motley Fool · 16h ago
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
A handful of dividend-paying businesses offer dividend yields above 4% at recent prices. CVS Health's dividend has exploded 142% over the past 10 years. Pfizer is America's largest pharmaceutical company by sales. Ares Capital is a business development company with a 9.2% dividend yield.
The Motley Fool · 17h ago
SCHD: A Must-Have In Every Dividend Portfolio
Schwab U.S. Dividend Equity ETF is a popular choice for income-oriented investors. SCHD offers exposure to dividend-paying firms with healthy balance sheets and a 3.46% dividend yield. The fund tracks the total return of the Dow Jones U. S. Dividend 100 Index.
Seeking Alpha · 19h ago
After Hours Most Active for May 3, 2024 : PFE, AAPL, CMCSA, RTX, DT, XOM, IAC, CSCO, VSTS, F, CTSH, GOOGL
NASDAQ · 1d ago
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
NASDAQ · 1d ago
Amgen stock rallies 13% on GLP-1 weight-loss drug update
Shares of Amgen stock rallies 13% on GLP-1 weight-loss drug update. The biotech giant expressed confidence about its GLp-1 drug candidate MariTide during its Q1 earnings call. Amgen's positive news helped push shares of its potential weight- loss drug rivals lower.
Seeking Alpha · 1d ago
Pfizer Inc.'s (NYSE:PFE) Price Is Out Of Tune With Revenues
Pfizer Inc.'s price-to-sales ratio of 2.7x is middle-of-the-road for the Pharmaceuticals industry in the U.S. Pfizer's revenue growth estimates for the next three years are expected to be 2.6% per year. The company's P/S ratio is in line with its industry peers.
Simply Wall St · 1d ago
BioNTech Earnings Preview: I Will Stay On The Sidelines
BioNTech is expected to report a significant decline in sales for the first quarter. The company's earnings per share is also expected to be worse compared to the previous year. BioNTech will announce its first-quarter earnings results on May 6. Investors should pay attention to the company's operating expenses and progress in its drug development pipeline.
Seeking Alpha · 1d ago
Amgen Stock Jumps on Obesity Drug Optimism. What Comes Next.
Amgen is trying to carve a niche for itself in the fast-growing market for weight-loss drugs. The company said it saw encouraging signs from its injectable obesity drug MariTide. The stock jumped 13% to $315.50 in premarket trading. Amgen said it will stop working on an experimental oral weight- loss pill.
Barron‘s · 1d ago
Analysts Conflicted on These Healthcare Names: InMode (INMD) and Pfizer (PFE)
TipRanks · 2d ago
Pfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been Waiting For'
Pfizer reported first-quarter earnings of 82 cents, down 33% year-over-year. The company reported sales of $14.9 billion, down 20%. Goldman Sachs maintains a Buy rating on the stock. Pfizer beat the consensus for adjusted EPS of 54 cents.
Benzinga · 2d ago
Moderna to seek parity for RSV shot as rivals lead in market
Moderna to seek parity for RSV shot as rivals lead in market. The company expects to win approval for its vaccine in H1 2024. Moderna's messenger-RNA-based shot is expected to be on par with more traditionally developed rival products. The vaccine is a pre-filled syringe.
Seeking Alpha · 2d ago
Pfizer Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 2d ago
Pfizer Price Target Raised to $29.00/Share From $28.00 by Morgan Stanley
Dow Jones · 2d ago
Morgan Stanley Maintains Equal-Weight on Pfizer, Raises Price Target to $29
Benzinga · 2d ago
Pfizer Price Target Raised to $36.00/Share From $33.00 by BMO Capital
Dow Jones · 2d ago
BMO Capital Reiterates Outperform on Pfizer, Raises Price Target to $36
Benzinga · 2d ago
More
Webull provides a variety of real-time PFE stock news. You can receive the latest news about Pfizer through multiple platforms. This information may help you make smarter investment decisions.
About PFE
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.